Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Cortria Corporation Stories

2008-10-28 09:00:39

Cortria Corporation, a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease, today announced that TRIA-662 has been selected as one of the Top 10 most promising cardiovascular projects in development. TRIA-662 is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. "We are excited that Windhover has selected...

2008-09-18 09:00:49

Cortria Corporation today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished cardiologists, clinical researchers and globally-recognized experts in the field of dyslipidemia. Members of the Cortria Scientific Advisory Board include: -Jean-Claude Tardif, M.D., Professor of Medicine and Director of the Research Center, Montreal Heart Institute (Chairman of Cortria Scientific Advisory Board) -H. Bryan Brewer, M.D., Director of Lipoprotein and...

2008-08-11 09:01:40

Cortria Corporation today announced the appointment of Gene Cefali, Pharm.D, Ph.D., as Senior Vice President of Clinical Pharmacology and Formulation Development. Dr. Cefali was previously Vice President of Lead Optimization at Kos Pharmaceuticals (acquired by Abbott Laboratories), where he played a major role in the development of Niaspan(R), a novel formulation of niacin and widely prescribed anti-dyslipidemic medicine, as well as three Niaspan(R) line-extension products. Dr. Cefali is a...

2008-07-14 09:01:11

Domain Associates and MVM Life Science Partners, two leading venture capital firms, today announced the appointment of Daniel Grau as CEO & Vice-Chairman and Richard King as Director of Cortria Corporation, a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease. TRIA-662, Cortria's first product candidate, is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder...